Shareholder Update July 2017

Jul 4th, 2017

In this issue: 

>> Starpharma sells Agrochemicals business to Agrium for $35M cash

>> DEP®  irinotecan outperforms irinotecan in multiple cancer models

>> DEP®  docetaxel, DEP®  cabazitaxel and scale-up facilities

>> AstraZeneca pays US$2M DEP®  milestone to Starpharma

>> VivaGel®  BV phase 3 results timing and commercialisation

>> VivaGel®  condom launched in Canada

>> Sale of Ansell's Sexual Wellness division

>> Starpharma News & Events

Download: Shareholder Update July 2017 (pdf file, 710kb)

Read More

VivaGel® BV phase 3 results timing and commercialisation

Jul 4th, 2017

Starpharma today announced revised timing for results of its two pivotal VivaGel® BV phase 3 trials for the prevention of recurrent bacterial vaginosis – now expected to be available in late July/early August 2017. 

Read More

Starpharma’s sale of its agrochemical business and technology, expands Agrium’s tech base

Jun 23rd, 2017

The sale of Starpharma’s agrochemical business was recently covered in Farm Weekly, highlighting the unique opportunity that Starpharma’s Priostar® dendrimer technology brings to the agrochemical market and the commercial value Agrium saw in the technology. In the article, Starpharma CEO Dr Jackie Fairley details the sale, including the patent transfer, total sale proceeds and the implications for the Company.

Go to article (external link)

Read More

Starpharma featured on Business IQ, Sky Business News

Jun 20th, 2017

Starpharma CEO Dr Jackie Fairley was interviewed on Sky Business News where she spoke to Business IQ host James Daggar-Nickson about dendrimer technologies and how the company develops products for a wide range of applications using the platform technology. Dr Fairley also discussed Australian innovation and the company's recent sale of its agrochemical business to global agricultural product giant Agrium.

Go to clip (external link)

Read More

Finance News Network: Starpharma sells Agrochemicals business for $35M

Jun 14th, 2017

Finance News Network noted Starpharma’s transaction to sell Starpharma Agrochemicals to Agrium Inc. for A$35M in cash consideration. The piece added that cash proceeds from the sale will allow Starpharma to focus on its core pharmaceutical development portfolio.

Go to the article (external link) 

Read More

Starpharma’s sale of its agrochemical business to Agrium for A$35M noted in The Land

Jun 14th, 2017

The sale of Starpharma’s agrochemical business was covered in The Land, with the article highlighting the innovation behind the Priostar® technology and how Agrium saw the acquisition as a strategic fit for their product portfolio. 

Go to article (external link)

Read More

Sale of Agrochemicals Business Investor Presentation

Jun 14th, 2017

Melbourne, Australia; 14 June 2017: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), will be holding an investor conference call today at 11am (AEST) to discuss the sale of its Agrochemicals business to Agrium Inc., for $35 million. A presentation featuring further information on the transaction is available.

Read More

Starpharma sells Agrochemicals business to Agrium for $35M

Jun 14th, 2017

Melbourne, Australia; 14 June 2017: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that it has completed a transaction to sell its agrochemicals and Priostar® business (Starpharma Agrochemicals) to Agrium, Inc., (Agrium) (NYSE: AGU, TSE: AGU) for A$35 million in cash consideration. The Starpharma Agrochemical business willl be operated by Agrium’s wholly-owned subsidiary, Loveland Products, Inc.

Read More

DEP® irinotecan outperforms irinotecan in multiple cancer models

Jun 6th, 2017

Melbourne, Australia; Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that its proprietary DEP® irinotecan has demonstrated significantly better anti‑tumour activity and increased survival compared with irinotecan in a variety of human colon cancer models. 

Read More

Starpharma receives DEP® milestone from AstraZeneca

Jun 2nd, 2017

Starpharma today announced it has received A$2.6 million from AstraZeneca following the achievement of the final preclinical milestone for its first DEP® candidate, a highly novel oncology molecule from AstraZeneca’s portfolio. 

Read More

Appendix 4C - Quarterly Cashflow Report

Apr 28th, 2017

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2017.

Read More

Starpharma featured on Ticky on Sky Business News

Apr 20th, 2017

Starpharma CEO Dr Jackie Fairley was interviewed on Ticky on Sky Business News where she discussed the company's VivaGel® portfolio, its DEP® drug delivery technology and its relationship with global pharmaceutical giant AstraZeneca.

 Go to the article (external link)

Read More